• Abbott's third-quarter 2026 net earnings fell 44% year over year to $920 million.
• Net sales rose 15% year over year to $13.01 billion.
• FDA approvals expanded its portfolio with the Libre Duo glucose-ketone sensor and TactiFlex Duo catheter for treating atrial fibrillation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610210730PR_NEWS_USPR_____CG76760) on October 21, 2026, and is solely responsible for the information contained therein.